ABSTRACT: The purpose was to test whether physicians can validly and reproducibly diagnose diabetic sensorimotor polyneuropathy (DSPN). Twelve physicians assessed 24 patients with diabetes mellitus (DM) on consecutive days (576 examinations) with physical features and voice disguised. Results were compared to gold standard 75% group diagnosis (dx) and a nerve conduction score (R5 NC nds). Masking of patients was achieved. Reproducibility measured by the kappa coefficient and compared to R5 NC nd varied considerably among physicians: median and ranges: signs 0.8 (0.32-1.0); symptoms 0.79 (0.36-1.0), and diagnoses 0.47 (0.33-0.84), both low and high scores indicating poor performance. There was substantial agreement between 75% group dx and confirmed NC abnormality (abn). As compared to R5 NC, individual physicians' clinical dx was excessively variable and frequently inaccurate. Study physician dx from signs and symptoms were excessively variable, often overestimating DSPN. Specific approaches to improving clinical proficiency should be tested. 42: 157-164, 2010 
Despite its common occurrence, diabetic sensorimotor polyneuropathy (DSPN) is not as sensitively and reliably diagnosed or its severity as adequately estimated as desirable. This conclusion is based mainly on three observations: (1) the great variability in the reported prevalence of DSPN-ranging from a few percentage points to more than 50% 1 ; (2) in cohort and epidemiology surveys, with some exceptions, 2 severity is usually not even evaluated; and (3) there is demonstrated variability of measured endpoints in therapeutic trials. 3 Llewelyn et al. 1 attribute prevalence variability to three reasons: ''differences in defining diabetic neuropathy, the tests used to assess neuropathy, and the type of patient population studied.'' Among the additional reasons is the possible lack of accuracy and reproducibility of clinical endpoint assessments by medical personnel. This issue of physician proficiency is studied here.
Neurologic signs, symptoms, and electrophysiologic measurements are the most commonly used instruments to diagnose DSPN.
2,4-6 Neurologic signs commonly used are decrease or loss of ankle reflexes or vibration sensation of feet, but also increasingly used are composite scores of neurologic signs (e.g., NIS [LL] ). 2 For neuropathy symptoms, individual or composite scores are used. Clinical neurophysiologic abnormalities used are nerve conduction (NC), quantitative sensation tests (QST), or autonomic tests (QAT). 2, 7, 8 Two histologic studies of biopsied tissue have been used: morphometric studies of biopsied nerve or intraepidermal nerve fiber densities. 9, 10 Consensus panels reviewing published data on DSPN found the endpoints listed above are useful in diagnosis (dx) and characterization of DSPN. 7, [11] [12] [13] In cohort studies or therapeutic trials a statistically significant association has been shown between neuropathic symptoms or signs and neuropathy tests, but the r 2 of the statistical association between the two varied considerably among studies. They usually accounted for only %5%-25% of the variability of the data. 3, 5, 14 Reproducibility, especially of the clinical evaluation of polyneuropathy (for its occurrence or severity), has been studied but usually only for individual (or at most for two or three) physicians. With agreement on diagnostic criteria and approaches to be used, high degrees of agreement have been recorded. 3, [14] [15] [16] Attributes of nerve conduction have been found to be variably reproducible measures; some (e.g., F-waves of lower limb nerves) show high degrees of reproducibility. 17, 18 This attribute, however, may not be an ideal measurement for DSPN, and other attributes may be more representative. 5 To assess whether expert physicians can validly and reproducibly diagnose DSPN based only on elicitation of symptoms and signs and without preliminary agreement on criteria and reference values, we judged that a prospective study was needed. In such a study a panel of physicians, without instruction or consensus development, would examine a representative group of patients with Abbreviations: R5 NC nds, summed five attributes of nerve conduction expressed as normal deviates, see legend to Table 1 DM and with and without DSPN. They would compare their evaluation of signs, symptoms, and dx to a gold standard group dx (the percentage to be set by an expert advisory panel) and to a confirmed (from 2/2 or 2/3 evaluations) abn of NC as measured by a composite score of nerve conduction abn.
MATERIALS AND METHODS
The design and conduct of the Cl vs. NPhys Trial is outlined in more detail in a separate communication. 19 In brief, we recruited a representative cohort of 24 volunteers with DM. Some did not have DSPN, and some had varying severities of DSPN. They were recruited from the Rochester Diabetic Neuropathy Study (RDNS) cohort, a crosssectional and longitudinal study of DM, diabetic microvessel complications, and their risk covariates in Olmsted County, MN. 15, 20 Patients were examined twice by each of the 12 study physicians (especially recruited for these prospective studies) and evaluated twice (or a third time) by NC, QST, and QAT [heart rate variation with deep breathing (HR db ) and sudomotor axon reflex test (QSART)]. Study physicians (neurologists and diabetologists) were experts in DSPN and came from Canada, Denmark, England, Wales, and the USA. Each study physician evaluated each of the 24 patients on November 24 and again on November 25, 2008 . We chose the largest number of patients who could reasonably be examined by 12 physicians in 1 day and then again on the second day, and who could have clinical neurophysiologic tests done within 3 weeks of the clinical evaluation. For disguise, patients wore surgical clothes, surgical caps, masks, and dark glasses, and their voices were electronically altered at first examination (Fig. 1) . Patients provided information only about symptoms related to neuropathy and not about type or duration of DM, known complications of DM, or treatment. Physicians examined patients as they saw fit without direction from study personnel but were asked to record the presence or absence of specific signs (decreased knee or ankle reflexes, decreased or absent sensation of touch pressure, vibration, joint position or movement, and pinprick), muscle weakness, neuropathy symptoms (''asleep numbness,'' ''prickling,'' ''burning'' or ''stabbing pain''), decreased reflexes, and whether patients had DSPN or not.
All clinical neurophysiological tests were done twice (and a third time if results were discordant for the dx of DSPN). Tests were performed by different technologists and instruments within the predetermined 6-week period. The attributes included in R5 NC were chosen because they are among the most representative of nerve conduction abnormalities in DSPN, i.e., peroneal motor nerve conduction velocity, compound muscle action potential amplitude and distal latency, tibial nerve motor distal latency, and sural sensory nerve action potential nerve amplitude. QST results were assessed with CASE IVb (WR Medical Electronics, Stillwater, MN). Heart rate deep breathing (HR db ) and Quantitative Sudomotor Axon Reflex Testing (QSART) were assessed by previously described approaches. 8 Each neurophysiologic evaluation was done without reference to clinical or previous test information.
Individual study physician's evaluation of signs and symptoms were compared to 75% group dx (the criterion set by the Expert Advisory Panel) 19 and to R5 NC nds abn, 21 judging agreement, and under-and overdiagnosis. Additionally, 75% group signs, symptoms, and dx were compared for agreement with R5 NC abn. For reproducibility, we employed the kappa coefficient. Descriptive statistics were also used for other purposes.
RESULTS
Choice of Percentage for Group dx of DSPN. Of the 40 Expert Advisory Panel canvassed, 16 physicians chose different percentage responses for decreased or absent ankle reflexes, vibration loss of toes, leg weakness, and neuropathy symptoms. On average, 3% chose 25%, 17.2% chose 50%, 43.8% chose 75%, and 36% chose 95%. Therefore, we accepted 75% as the level to be used for group signs, symptoms, and dx.
Conduct of Study. The 12 study neuromuscular physicians performed the 576 clinical examinations over a period of 2 days without need to call on ''standby'' physicians or patients, and neurophysiologic tests were performed within the set 6-week time period. At second examination, only a small percentage of patients were recognized by distinctive physical features or medical histories (14.9%) or recall of specific symptoms or findings (7.6%). Thus, independent and masked evaluation was achieved for almost all second clinical evaluations.
Demographic and Disease Characteristics of the 24
Patients. The patients were 17 men and 7 women, whose mean age was 62.5 years (SD 8.7 years); 10 had type 1, and 14 had type 2 DM for an average duration of 21.3 years (SD 13.3 years). Their average A1C value over previous longitudinal studies was 7.4% (SD 1.0%). The study cohort for the Cl vs. NPhys Trial was chosen so that one-half had and one-half did not have DSPN by a composite score of nerve conduction criteria (for calculation of R5 NC nd, see footnote to Table 1 ). Sixteen had retinopathy (nine mild background, four severe background, and two proliferative). Three patients had nephropathy (two stage 1 and one stage 3).
Comparative Performance Between the Two Gold
Standard Evaluations: 75% Group dx and R5 NC abn. In Table 1 we summarize the frequency of endpoint abnormalities for each of the 24 patients, showing numbers of clinical abnormal evaluations of the 12 Â 2 ¼ 24 physician examinations of each patient and the number of confirmed nerve test abnormalities (2/2 or 2/3). We have shaded the data boxes meeting !75% group dx, confirmed R5 NC abn, and other combined test abnormalities.
On visual inspection of the columns marked Diagnosis and R5 NC nds (the two gold standard evaluations) in Table 1 , note that 12 of 24 patients were abnormal by R5 NC abn, and eight of these were also abnormal by 75% group dx and one was abnormal by 75% group dx only. This result suggests a reasonably close agreement between the two gold standard criteria, with R5 NC abn being somewhat more sensitive. However, there is a difference between them. For R5 NC nds abn there is a more clean separation of normal from abnormal. Thus, for R5 NC abn, all but two were abnormal by 2/2 abnormalities and for those without NC abn they were so categorized by 0/2 abnormalities. By contrast, for 75% group dx there was a greater overlap of abnormal evaluations between affected and unaffected persons. This lack of clean separation of affected from unaffected patients was also observed for signs and symptoms (Table 1 and in  full Tables 2 and 3 ; Supporting Information Material). The variability in elicitation of signs and symptoms and dx is discussed in more detail in the full tables in electronic Appendix.
Agreement between the first two gold standard endpoints using the kappa coefficient was 0.83 for R5 NC nds abn and 0.73 for the 75% group dx (excellent and good reproducibility). From these results it would appear the R5 NC nds abn is more sensitive and perhaps somewhat more reproducible for the dx of DSPN than is 75% group dx.
Comparative Performance of 75% Group Signs as
Compared to 75% Group dx or R5 NC abn. As compared to 75% group dx, agreement was obtained by 75% signs in nine cases, with overdiagnosis in nine cases and underdiagnosis in 0 cases ( Table  1) . As compared to R5 NC nds abn, the figures were 10, 8, and 2 (Table 1 ). It appears that by either gold standard criterion, 75% signs markedly overestimate the dx of DSPN when compared to gold standard criteria. The reproducibility of 75% signs provided a kappa coefficient of 0.56.
Comparative Performance of 75% Group Symptoms as
Compared to 75% Group dx or R5 NC abn. As compared to 75% group dx, 75% group symptoms agreed with this diagnoses in five of nine cases. It was overdiagnosed in one case and underdiagnosed in four cases (Table 1) . For R5 NC nds abn, the figures were 5, 1, and 7 cases ( Table 1 ). The data suggest that 75% group symptoms underdiagnosed DSPN as compared to gold standard criteria. The reproducibility of 75% group symptoms (j ¼ 0.89) was very high.
Comparative Performance of Individual Investigators as Compared to R5 NC abn or 75% Group dx. The most striking observation of individual physician performance was the excessive variability of their estimation of signs, symptoms, and diagnoses as compared to R5 NC abn or 75% group dx (Tables  1-3 ; some of the data in Supporting Information data). To illustrate this point, we list median values (and ranges) of correct dx at first examination as compared to the gold standard criteria of R5 NC FIGURE 1. Members of the surveillance team illustrate the dress and electronic voice distortion used at first examination to allow masked assessment of reproducibility on a subsequent evaluation the next day. This is described in more detail in the text. . A column for patients with both signs and symptoms is not provided since it would be identical to the column for symptoms.
nds !95th: signs 13 (12) (13) (14) (15) (16) (17) (18) (19) ; symptoms 15 (13) (14) (15) (16) (17) (18) ; and diagnoses 16 (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (Table 2 ). In Table 2 we show the number of correct, under-, and overdiagnoses of each of the 12 study physicians at first and second evaluations and as compared to R5 NC abn (Table 2) or as compared to 75% group abn (Table 3) . Tables 2 and 3 also provide kappa coefficients for each investigator. It is important to note that the two physicians who had complete agreement (1.0; physicians 5 and 11, Table 2 ) obtained this score by overdiagnosing DSPN by both gold standard criteria.
DISCUSSION
The prevalence of DM appears to be increasing. 22, 23 Whether microvascular complications, including DSPN, are also increasing needs to be tested. For this purpose, accurate estimation of the occurrence and severity of DSPN is needed. It is also needed to test putative therapies. Like retinopathy and nephropathy, the complication of DSPN may begin insidiously over long times and with few or no symptoms. 2, 3, 20 When DSPN develops to an overt and expressed degree, physicians presumably have little difficulty recognizing its presence by characteristic symptoms (''asleep-numbness,'' ''prickling,'' ''burning,'' ''sticking,'' ''stabbing,'' or ''deep aching pain'' or loss of sensation in characteristic distal lower limb distributions), neurologic signs (decreased or absent ankle or knee reflexes, distal lower limb sensory loss, sudomotor loss, and distal muscle weakness in more severe cases). However, it may be difficult and in some cases impossible to recognize physiologic degrees of DSPN by clinical approaches, because a variable percentage of cases are asymptomatic and clinical methods of assessment are not sufficiently expressed, valid, or reproducible to recognize this minimal degree of involvement. The recently proposed case definition of distal polyneuropathy (including DSPN) developed by an AAN consensus committee and based on review of the medical literature might be considered by whether it would serve as the minimal criteria for DSPN. This consensus case definition states that the ''highest likelihood of polyneuropathy occurs with a combination of multiple symptoms, multiple signs, and abnormal electrodiagnostic studies. '' 13 Whereas this case definition is intuitively correct, it probably does not serve well as a specific minimal criterion for the dx of DSPN for the following reasons: (1) specificity is emphasized over sensitivity, e.g., patients with unequivocal electrophysiologic or other valid test abnormalities but who do not have signs and symptoms would be excluded from the dx; (2) the emphasis on both ''multiple signs'' and ''multiple symptoms'' would exclude patients from dx when they had only symptoms or signs or had single symptoms or signs; (3) the specific signs or symptoms or how they are to be graded as abnormal are not defined; and (4) specific criteria for how electrodiagnostic criteria are to be judged and by what reference criteria are not given.
In this study we assessed the comparative performance of individual neuromuscular physicians' proficiency to accurately and reproducibly judge neurologic signs, symptoms, and dx of DSPN as compared to gold standard 75% group dx or R5 NC abn. From its unique design features and from elicited responses from study physicians, it appears that the study was sufficiently rigorous to assess validity and reproducibility. It is important to also ask whether the chosen gold standard evaluations are themselves adequate to recognize DSPN. In support of 75% group dx as a gold standard criterion, we list the historical use of symptoms and signs for this purpose, the conclusions of published consensus panels, and the judgment of our expert advisory panel. Likewise, for use of nerve conduction abn we list historical precedence and extensive correlative studies (reviewed in the introduction). We deliberately used a composite score of nerve conduction to ensure that multiple attributes of several nerves and functions and in an appropriate anatomical region (the leg) were tested and that results were corrected for applicable variables from study of a large and appropriate reference cohort of healthy subjects drawn from the same population as were the patients. That the two chosen gold standard endpoints are appropriate endpoints also came from the close association between diagnoses based on the two criteria.
This study has shown that the 75% group dx correlates closely with R5 NC abn but apparently detects a less severe degree of DSPN. That abn of nerve conduction is a more sensitive diagnostic criterion has previously been demonstrated (see introduction). Although the 75% group dx is useful for the dx of DSPN for this study, it is of course impractical for use in epidemiologic surveys, controlled therapeutic trials, or medical practice.
How accurate, invariant, and reproducible are individual physicians' evaluations? Although the reproducibility of the judgments about DSPN by individual physicians ranged from good to very good, there was considerable and excessive variability among physician judgment of signs, symptoms, and dx. Some of the best kappa scores of reproducibility were at the expense of overcalling abn, giving a wrong indication of polyneuropathy. By either gold standard criterion the judgment of physicians about neuropathic signs, symptoms, and diagnoses was excessively variable. The problem was especially problematic for signs that were markedly overestimated. This overestimation of neurologic signs is not readily explained.
The study also provides information on the use of QSTs, HR db , and QSART for the dx of DSPN. In this cohort, none of these measures performed as well as did R5 NC nds-an observation also found in our RDNS cohort study of persons with DM in Olmsted County. 3, 14, 20 These results, therefore, suggest that small fiber measures, i.e., QSTs of small sensory fibers, HR db , and QSART, may not be as sensitive as large fiber measures for the detection of DSPN in community patients with DSPN.
If clinical approaches are to be used (and we think they should be), neurologic assessments and judgments of clinical signs, symptoms, and dx need to be improved.
Assuming that our study physicians are among the best clinical examiners in medical practice, the excessive variability and overdiagnoses, especially of signs, is of considerable concern because the problem may be even greater in general medical practice. Recognizing that individual physicians tend to overdiagnose neuropathic findings, symptoms, and dx and that there is excessive variability of their judgments suggests that changes need to be made to improve clinical assessments. The following approaches might be considered for this purpose: (1) Adoption of the rule that physicians' grading of signs and symptoms should aim to be a direct indication of polyneuropathy-not an indication of physiologic abn, e.g., due to age, gender, or other anthropomorphic variables; (2) Physicians might grade signs and symptoms, aiming for comparable degrees of specificity and sensitivity; (3) Physicians might school themselves to identify abn of their clinical evaluations with reference to NC or other clinical neurophysiologic test abnormalities; (4) Prior to protocol studies, instruction sessions, consensus development, and certification might precede conduct of the study; (5) Physicians who have schooled themselves by NC, QST, and QAT standards might provide peer clinical evaluations of patients compared to which study physicians could judge their performance. Such proficiency testing is extensively used by the American College of Pathologists 24 ; and (6) More standard and validated tests with reference values could be developed.
